Transesophageal echocardiography-guided cardioversion of atrial fibrillation.

Transesophageal echocardiography-guided anticoagulation management of patients with atrial fibrillation undergoing cardioversion has evolved over the past decade as a viable alternative to conventional anticoagulation management. Its use grew out of a need for a more predictable, dependable, and convenient approach to this difficult management dilemma, which has become increasingly prevalent in practice as an increasing number of patients present to clinics and hospitals with atrial fibrillation. In addition to its use in risk stratification of patients scheduled to undergo cardioversion, this management strategy allows for early cardioversion, which enables a minimal delay in proceeding from the diagnosis to the institution of therapy (electrical cardioversion). This review explores the evolution of the transesophageal echocardiography-guided strategy, the advantages and disadvantages of its use, and possible modifications to the strategy that would allow for a more convenient, practical, and more widely acceptable approach in the near future.